Influence of glycyrrhetinic acid on the pharmacokinetics of warfarin in rats

References

• Cai Y, Xu Y, Chan HF, et al. (2016). glycyrrhetinic acid mediated drug delivery carriers for hepatocellular carcinoma therapy. Mol Pharm 13:699–709.
   PubMed Web of Science ®Google Scholar
• Cao L, Ding W, Jia R, et al. (2017). Anti-inflammatory and hepatoprotective effects of glycyrrhetinic acid on CCl4-induced damage in precision-cut liver slices from Jian carp (Cyprinus carpio var. jian) through inhibition of the nf-kƁ pathway. Fish Shellfish Immunol 64:234–42.
   PubMed Web of Science ®Google Scholar
• Chen D, Bellussi LM, Cocca S, et al. (2017). Glycyrrhetinic acid suppressed hmgb1 release by up-regulation of Sirt6 in nasal inflammation. J Biol Regul Homeost Agents 31:269–77.
   PubMed Web of Science ®Google Scholar
• Eriksson N, Wadelius M. (2012). Prediction of warfarin dose: why, when and how?. Pharmacogenomics 13:429–40.
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Zhang YY, Ge GB, et al. (2010). Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol 69:193–9.
   PubMed Web of Science ®Google Scholar
• Ge B, Yang D, Wu X, et al. (2018). Cytoprotective effects of glycyrrhetinic acid liposome against cyclophosphamide-induced cystitis through inhibiting inflammatory stress. Int Immunopharmacol 54:139–44.
   PubMed Web of Science ®Google Scholar
• Guo C, Xue S, Zheng X, et al. (2018). The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats. Xenobiotica 48:400–6.
   PubMed Web of Science ®Google Scholar
• Hokusai V, Buller HR, Decousus H, et al. (2013). Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–15.
   PubMed Web of Science ®Google Scholar
• Hussain H, Green IR, Shamraiz U, et al. (2018). Therapeutic potential of glycyrrhetinic acids: a patent review (2010–2017). Expert Opin Ther Pat 28:383–98.
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Zhang ZY. (1997). Human P450 metabolism of warfarin. Pharmacol Ther 73:67–74.
   PubMed Web of Science ®Google Scholar
• Kim S-B, Cho H-J, Kim YS, et al. (2015). Modulation of cytochrome P450 activity by 18β-glycyrrhetic acid and its consequence on buspirone pharmacokinetics in rats. Phytother Res 29:1188–94.
   PubMed Web of Science ®Google Scholar
• Li A, Ma N, Zhao Z, et al. (2016). Glycyrrhetinic acid might increase the nephrotoxicity of bakuchiol by inhibiting cytochrome P450 isoenzymes. PeerJ 4:e2723.
   PubMed Web of Science ®Google Scholar
• Liu L, Xiao J, Peng ZH, Chen Y. (2011). In vitro metabolism of glycyrrhetic acid by human cytochrome P450. Yao Xue Xue Bao 46:81–7.
   PubMedGoogle Scholar
• Lv QL, Wang GH, Chen SH, et al. (2015). In vitro and in vivo inhibitory effects of glycyrrhetinic acid in mice and human cytochrome P450 3A4. Int J Environ Res Public Health 13:84.
   PubMed Web of Science ®Google Scholar
• Mueller K, Bernaitis N, Badrick T, Anoopkumar-Dukie S. (2017). HAS-bled predicts warfarin control in Australian patients treated for deep vein thrombosis. Basic Clin Pharmacol Toxicol 120:299–302.
   PubMed Web of Science ®Google Scholar
• Shen C, Huang X, Li J, et al. (2016). Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs. Xenobiotica 46:530–41.
   PubMed Web of Science ®Google Scholar
• Utoh M, Kusama T, Miura T, et al. (2018). R-warfarin clearances from plasma associated with polymorphic cytochrome P450 2C19 and simulated by individual physiologically based pharmacokinetic models for 11 cynomolgus monkeys. Xenobiotica 48:206–10.
   PubMed Web of Science ®Google Scholar
• Wang L, Yang R, Yuan B, et al. (2015). The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. Acta Pharm Sin B 5:310–5.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang X, Liu F, Wang M, Qin S. (2017). The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. Pharm Biol 55:1863–67.
   Google Scholar
• Weir MR, Haskell L, Berger JS, et al. (2018). Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function. Clin Nephrol 89:314–29.
   PubMed Web of Science ®Google Scholar
• Xu B, Wu GR, Zhang XY, et al. (2017). An overview of structurally modified glycyrrhetinic acid derivatives as antitumor agents. Molecules 22:924.
   Web of Science ®Google Scholar
• Yacobi A, Lai CM, Levy G. (1980). Comparative pharmacokinetics of coumarin anticoagulants XLV: Pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin and phenylbutazone in rats. J Pharm Sci 69:14–20.
   PubMed Web of Science ®Google Scholar
• Yamaori S, Takami K, Shiozawa A, et al. (2015). In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod–warfarin interaction. Biol Pharm Bull 38:441–7.
   PubMed Web of Science ®Google Scholar
• Ye H, Sui D, Liu W, et al. (2019). Effects of CYP2C11 gene knockout on the pharmacokinetics and pharmacodynamics of warfarin in rats. Xenobiotica 1–7.
   Web of Science ®Google Scholar
• Zakharyants AA, Burmistrova OA, Poloznikov AA. (2017). The use of human liver cell model and cytochrome P450 substrate-inhibitor panel for studies of dasatinib and warfarin interactions. Bull Exp Biol Med 162:515–9.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang X, Wang X, Zhao M. (2018). Influence of andrographolide on the pharmacokinetics of warfarin in rats. Pharm Biol 56:351–6.
   PubMed Web of Science ®Google Scholar
• Zhao K, Ding M, Cao H, Cao ZX. (2012). In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates. J Pharm Pharmacol 64:1445–51.
   PubMed Web of Science ®Google Scholar